Partnership between leading scientific service
providers enhances offerings for pharmaceutical clients
KATY,
Texas, June 25, 2024 /PRNewswire/
-- ToxStrategies, a best-in-class, multidisciplinary
scientific consulting firm, today announced the acquisition of
Clintrex Research Corporation. Founded in 2008 by Dr. C.
Warren Olanow, Dr. Karl Kieburtz, and Cornelia Kamp, Clintrex operationalizes clinical
and regulatory development pathways for new treatments for
neurodegenerative and other central nervous system diseases.
ToxStrategies is a portfolio company of Renovus Capital Partners.
Terms of the transaction were not disclosed.
ToxStrategies partnered with Renovus Capital Partners in
November 2022 with the goal of
expanding its existing client base and developing new end markets.
The acquisition of Clintrex by ToxStrategies brings together two
best-in-class firms within the life sciences industry, with a
unified focus on providing integrated teams to solve the
multifaceted problems and challenges faced by our clients,
particularly in the drug development space. Drs. Olanow and
Kieburtz will continue to lead Clintrex as a Division of
ToxStrategies.
Clintrex staff includes world-renowned experts in various
aspects of drug development who collaborate with clients to
identify and solve pre-clinical science, clinical trial,
biostatistical and regulatory issues that are critical to product
development and approval. This internationally recognized team of
experts has developed a unique and proven approach for conducting
clinical trials that serves to minimize variability, facilitate
recruitment, require smaller sample sizes, and increase the
likelihood of accurately detecting an accurate and reliable
result.
"We are proud to welcome Clintrex physicians, scientists and
regulatory specialists to our growing team of toxicologists,
epidemiologists, biostatisticians, engineers, and health economics
and outcome research (HEOR) analysts working to develop and assist
with FDA approval of life-changing therapies, as well as providing
expertise in the optimization of the biopharmaceutical cold chain
for novel, fragile, and temperature controlled therapies," said
President of ToxStrategies, Dr. Laurie
Couture Haws, Ph.D., DABT, ATS.
"We are delighted to partner with ToxStrategies and its
associated companies," said Dr. C Warren
Olanow MD, FRCPC, FRCP (hon), CEO of Clintrex Research
Corporation. "This partnership will enable us to provide a combined
approach for assisting biotech and pharmaceutical companies in
their development programs. This approach will include preclinical
toxicology, health outcome and epidemiologic approaches, in
addition to the basic science, clinical trial, operational and
regulatory assistance we currently provide. Together, we believe
this will facilitate the development process and increase the
likelihood that promising new therapies will become available to
help patients with these disorders."
"We are excited to continue delivering outstanding services to
our existing and future collaborators, and to have the chance to
expand the breadth of capabilities working as part of
ToxStrategies," said Dr. Karl
Kieburtz, MD, MPH, Co-founder and Chair of the Clintrex
Board of Directors.
"ToxStrategies has benefitted from being one of several Renovus
portfolio companies in the life sciences industry, giving it access
to a vast network of relationships, capabilities, and industry
expertise," said Jesse Serventi, a
founding partner at Renovus Capital Partners. "We are now excited
to support ToxStrategies' acquisition of Clintrex, which brings
together two world class service providers to support the full
pharmaceutical development pipeline, particularly in the
neurodegenerative and neurological diseases space. We are confident
that this acquisition will create numerous growth opportunities for
the combined company."
About ToxStrategies
ToxStrategies is a
multidisciplinary scientific consulting firm specializing in
toxicology, epidemiology, exposure sciences, industrial hygiene and
safety, regulatory compliance, and health economics and outcomes
research. They are a cutting-edge firm that strives to develop
innovative solutions to address the complex scientific, technical,
and regulatory challenges confronting their clients. ToxStrategies
has a reputation for applying sound science and novel approaches
tailored to meet the specific needs of their clients, whether a
rapid response or a comprehensive analysis is required. The
ToxStrategies' team of toxicologists, epidemiologists, industrial
hygienists, engineers, exposure scientists, modelers,
biostatisticians, information specialists, and regulatory
specialists are recognized as leaders in their respective
disciplines and bring a high level of technical expertise to every
project. ToxStrategies has extensive experience assessing potential
health risks associated with exposures to a wide variety of
consumer products, food ingredients and additives, pharmaceuticals,
medical devices, pesticides, industrial chemicals and environmental
contaminants. ToxStrategies is headquartered in Texas and has offices and remote consultants
throughout the US, Canada and
England. For more information,
please visit www.toxstrategies.com.
About Clintrex
Clintrex provides scientific, clinical
trial, operational, and regulatory assistance to pharmaceutical and
biotech companies engaged in the development of new therapies for
central nervous system disorders. Clintrex principals have led
clinical trials and provided regulatory assistance for companies in
the US, Europe and Japan which developed, small molecules,
devices and biologics that have resulted in the approval of
multiple therapies for various neurological disorders. Its team
includes leaders in the global scientific, neurological and
regulatory communities. For more information, please visit
www.clintrex.com.
About Renovus Capital Partners
Founded in 2010,
Renovus Capital Partners is a lower middle-market private equity
firm specializing in the Knowledge and Talent industries. From its
base in the Philadelphia area,
Renovus manages over $1.5 billion
across its three sector focused funds and other strategies. The
firm's current portfolio includes over 25 U.S. based businesses
specializing in education and training, healthcare services,
technology services and professional services. Renovus typically
partners with founder-led businesses, leveraging its experience
within the industry and access to debt and equity capital to make
operational improvements, recruit top talent, pursue add-on
acquisitions and oversee strategic growth initiatives. Visit us at
www.renovuscapital.com and follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/toxstrategies-acquires-clintrex-research-corporation-302181076.html
SOURCE Renovus Capital Partners LLC